3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Interventions
enzalutamide
2
apalutamide
2
Pluvicto
2
Leuprolide
2
Androgen Antagonists
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
relugolix
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
luprolide acetate gel depot
1
larotrectinib
1
ipatasertib
1
gallium 68 PSMA-11
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Trastuzumab
1
Sunitinib
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Prostatic Neoplasms
×
relugolix
×
Clear all
NCT03085095
2022-01-18
HERO
Myovant Sciences GmbH
Phase 3
Completed
1,134 enrolled
38 charts
1 FDA